|Bid||1.440 x 0|
|Ask||1.450 x 0|
|Day's Range||1.440 - 1.450|
|52 Week Range||1.270 - 1.850|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||11.80|
|Earnings Date||Jun 18, 2020|
|Forward Dividend & Yield||0.18 (12.41%)|
|Ex-Dividend Date||Sep 01, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 0321.HK
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the publication of two new research papers highlighting approaches to improve the potential therapeutic effect of its novel CD37-targeting radioimmunoconjugate Humalutin® (177Lu-DOTA-NNV003) in B-cell malignancies, such as Non-Hodgkin Lymphoma (NHL).
DALLAS, February 03, 2022--AECOM (NYSE: ACM), the world’s trusted infrastructure consulting firm, today announced that its joint venture with Michael Baker International has been awarded an indefinite delivery, indefinite quantity (IDIQ) contract to provide architecture and engineering services in support of environmental compliance programs with the U.S. Naval Facilities Engineering Systems Command (NAVFAC).
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...